Down-regulation of RB1 and TP53 as potential predicting biomarkers for castration-resistant prostate cancer (CRPC): Indonesian retrospective cohort study
| Autor: | Indrawarman Soerohardjo, Sumadi Lukman Anwar, Didik Setyo Heriyanto, Irianiwati Widodo, Andy Zulfiqqar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Retrospective cohort study General Medicine medicine.disease Androgen deprivation therapy 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Castration medicine.anatomical_structure chemistry Downregulation and upregulation Prostate 030220 oncology & carcinogenesis Internal medicine medicine 030211 gastroenterology & hepatology Surgery business Pathological Hormone |
| Zdroj: | Annals of Medicine and Surgery. 60:549-554 |
| ISSN: | 2049-0801 |
| DOI: | 10.1016/j.amsu.2020.11.017 |
| Popis: | Introduction Androgen deprivation therapy (ADT) has remained the first line strategy for treatment of advanced prostate cancers. Despite the profound efficacy of ADT in preventing clinical remission, 30–50% of advanced prostate cancer will develop resistance to hormonal deprivation therapy. This study aimed to evaluate the potential role of RB1 and TP53 expressions as biomarkers for predicting time to castration-resistant prostate cancer (CRPC). Methods The clinical and pathological data of patients with prostate cancer were collected retrospectively from Dr. Sardjito General Hospital, Yogyakarta. Between 2015 and 2019, a total of 36 patients who received castration were included. Expressions of mRNA of RB1 and TP53 from primary tumors were quantified using quantitative Real Time Polymerase Chain Reaction (qRT-PCR). Results The expressions of mRNA of RB1 and TP53 increased in prostate cancer tissues compared to hyperplastic prostates and significantly downregulated in metastatic prostate cancers (p Conclusions Low expression of mRNA of RB1 and TP53 has been shown to be a potential marker of shorter time to develop CRPC in patients with advanced stages of prostate cancer treated with ADT. Meanwhile, ISUP score >4 were not shown predictive value on time to CRPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|